PAPL vs IVF

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 04, 2026

PAPL

39.1
AI Score
VS
PAPL Wins

IVF

29.2
AI Score

Investment Advisor Scores

PAPL

39score
Recommendation
AVOID NEW MONEY

IVF

29score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric PAPL IVF Winner
Forward P/E 0 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth -16.7% 16.7% IVF
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 39.1/100 29.2/100 PAPL
Profit Margin -114.1% -92.3% IVF
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY AVOID NEW MONEY Tie

Relative Price Performance (Last 90 Days)

PAPL 1M: -3.0% · 3M: -14.0% IVF 1M: +175.3% · 3M: +91.5%

Current Technical Phase

PAPL

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 54

RSI (14): 54.2 · Price: $0.98

IVF

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 82

RSI (14): 82.0 · Price: $2.03

Fundamentals Snapshot

Metric PAPL IVF
Market Cap — —
Forward P/E 24.5 -0.1
Trailing P/E — 0.0
Revenue (TTM) — —
Revenue Growth -0.2% 0.2%
Gross Margin 1.0% 0.4%
Operating Margin -1.4% -0.6%
EPS -1.94 511.80
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, PAPL is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.